New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.

Abstract:

:The microenvironments of leukemia and cancer are critical for multiple stages of malignancies, and they are an attractive therapeutic target. While skeletal abnormalities are commonly seen in children with acute lymphoblastic leukemia (ALL) prior to initiating osteotoxic therapy, little is known about the alterations to the bone marrow microenvironment during leukemogenesis. Therefore, in this study, we focused on the development of precursor-B cell ALL (pre-B ALL) in an immunocompetent BCR-ABL1+ model. Here we show that hematopoiesis was perturbed, B lymphopoiesis was impaired, collagen production was reduced, and the number of osteoblastic cells was decreased in the bone marrow microenvironment. As previously found in children with ALL, the leukemia-bearing mice exhibited severe bone loss during leukemogenesis. Leukemia cells produced high levels of receptor activator of nuclear factor κB ligand (RANKL), sufficient to cause osteoclast-mediated bone resorption. In vivo administration of zoledronic acid rescued leukemia-induced bone loss, reduced disease burden and prolonged survival in leukemia-bearing mice. Taken together, we provide evidence that targeting leukemia-induced bone loss is a therapeutic strategy for pre-B ALL.

journal_name

Leukemia

journal_title

Leukemia

authors

Cheung LC,Tickner J,Hughes AM,Skut P,Howlett M,Foley B,Oommen J,Wells JE,He B,Singh S,Chua GA,Ford J,Mullighan CG,Kotecha RS,Kees UR

doi

10.1038/s41375-018-0144-7

subject

Has Abstract

pub_date

2018-11-01 00:00:00

pages

2326-2338

issue

11

eissn

0887-6924

issn

1476-5551

pii

10.1038/s41375-018-0144-7

journal_volume

32

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • Role of catalase in monocytic differentiation of U937 cells by TPA: hydrogen peroxide as a second messenger.

    abstract::Human promonocytic cell line U937 cells can be induced to differentiate into macrophages by treatment with 12-O-tetradecanoylphorbol-13-acetate (TPA). TPA treatment induced the expression of the monocytic differentiation markers CD11b and CD36, with concomitant morphological changes. Moreover, TPA enhanced reactive ox...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.353

    authors: Yamamoto T,Sakaguchi N,Hachiya M,Nakayama F,Yamakawa M,Akashi M

    更新日期:2009-04-01 00:00:00

  • Polyclonal expansion of T-cell receptor-gamma delta+ T lymphocytes associated with neutropenia and thrombocytopenia.

    abstract::A patient with large granular lymphocyte (LGL) expansion (T-gamma lymphocytosis), neutropenia and thrombocytopenia was studied longitudinally. Analysis of peripheral blood mononuclear cells (PBMC) demonstrated an unusual large proportion of CD3+ T-lymphocytes expressing a gamma delta T-cell receptor (TcR-gamma delta)....

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: van Oostveen JW,Breit TM,de Wolf JT,Brandt RM,Smit JW,van Dongen JJ,Borst J,Melief CJ

    更新日期:1992-05-01 00:00:00

  • The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.

    abstract::Improved survival of patients with acute lymphoblastic leukemia (ALL) has emerged from identifying new prognostic markers; however, 20% of children still suffer recurrence. Previously, the altered expression of Fat1 cadherin has been implicated in a number of solid tumors. In this report, in vitro analysis shows that ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.319

    authors: de Bock CE,Ardjmand A,Molloy TJ,Bone SM,Johnstone D,Campbell DM,Shipman KL,Yeadon TM,Holst J,Spanevello MD,Nelmes G,Catchpoole DR,Lincz LF,Boyd AW,Burns GF,Thorne RF

    更新日期:2012-05-01 00:00:00

  • Gene therapy against retroviral diseases.

    abstract::Eventually, gene therapy may be a valid option for chronic viral infections, including retroviral infections. Human retroviral diseases fit two categories: (1) those that result from a monoclonal outgrowth of a human T-cell leukemia virus type I (HTLV-I)-infected cell, as in the case of adult T cell leukemia (ATL); an...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:

    authors: Essex M,Matsuda Z,Yu X,Lee TH

    更新日期:1995-10-01 00:00:00

  • Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.

    abstract::Insertional activation of cellular proto-oncogenes by replication-defective retroviral vectors can trigger clonal dominance and leukemogenesis in animal models and clinical trials. Here, we addressed the leukemogenic potential of vectors expressing interleukin-2 receptor common gamma-chain (IL2RG), the coding sequence...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.118

    authors: Modlich U,Schambach A,Brugman MH,Wicke DC,Knoess S,Li Z,Maetzig T,Rudolph C,Schlegelberger B,Baum C

    更新日期:2008-08-01 00:00:00

  • In vivo recruitment of GM-CSF-response myelopoietic progenitor cells by interleukin-3 in aplastic anemia.

    abstract::Previous studies have indicated that colony-stimulating factors may stimulate myelopoiesis and thus increase the number of circulating white blood cells in patients with hematopoietic failure including aplastic anemia. However, long-term administration of the factor was required to maintain its response. In the presen...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Herrmann F,Lindemann A,Raghavachar A,Heimpel H,Mertelsmann R

    更新日期:1990-10-01 00:00:00

  • Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias.

    abstract::The impact of ten-eleven-translocation 2 (TET2) mutations on response to azacitidine (AZA) in MDS has not been reported. We sequenced the TET2 gene in 86 MDS and acute myeloid leukemia (AML) with 20-30% blasts treated by AZA, that is disease categories wherein this drug is approved by Food and Drug Administration (FDA...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.71

    authors: Itzykson R,Kosmider O,Cluzeau T,Mansat-De Mas V,Dreyfus F,Beyne-Rauzy O,Quesnel B,Vey N,Gelsi-Boyer V,Raynaud S,Preudhomme C,Adès L,Fenaux P,Fontenay M,Groupe Francophone des Myelodysplasies (GFM).

    更新日期:2011-07-01 00:00:00

  • Analysis of the immunoglobulin heavy chain gene variable region of CD5-positive and -negative diffuse large B cell lymphoma.

    abstract::We analyzed nucleotide sequence and intraclonal diversity of the rearranged immunoglobulin heavy chain gene variable region (VH gene) of CD5+ and CD5- diffuse large B cell lymphoma (DLBCL) to clarify the cell origin of de novo CD5+ DLBCL. Ten cases of CD5+ DLBCL and 29 cases of CD5- DLBCL were analyzed. The frequencie...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402031

    authors: Nakamura N,Kuze T,Hashimoto Y,Hara Y,Hoshi S,Sasaki Y,Shirakawa A,Sato M,Abe M

    更新日期:2001-03-01 00:00:00

  • Do P-glycoprotein and major vault protein (MVP/LRP) expression correlate with in vitro daunorubicin resistance in acute myeloid leukemia?

    abstract::Two proteins that have been correlated with the occurrence of multidrug resistance in acute myeloid leukemia (AML) are P-glycoprotein (Pgp) and the major vault protein (Mvp/LRP). With the purpose of further quantifying the potential contributions of Pgp-mediated drug efflux and Mvp/LRP to drug resistance in AML we hav...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401331

    authors: Broxterman HJ,Sonneveld P,Pieters R,Lankelma J,Eekman CA,Loonen AH,Schoester M,Ossenkoppele GJ,Löwenberg B,Pinedo HM,Schuurhuis GJ

    更新日期:1999-02-01 00:00:00

  • Collection, analysis and transplantation of Ph-negative blood precursor cells in chronic myeloid leukemia.

    abstract::This work represents an update of our experience on mobilization and transplantation of peripheral blood progenitor cells (PBPC) collected during the early recovery phase after chemotherapy in patients with chronic myelogenous leukemia. The collection of Ph-negative precursor cells occurred in 13/19 (68%) patients mob...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Frassoni F,Carella AM

    更新日期:1996-06-01 00:00:00

  • Tissue repair using allogeneic mesenchymal stem cells for hemorrhagic cystitis, pneumomediastinum and perforated colon.

    abstract::Mesenchymal stem cells (MSC) possess anti-inflammatory properties and participate in tissue repair. We used MSC to heal therapy-induced tissue toxicity. Ten consecutive patients, treated with MSC due to tissue toxicity following allogeneic hematopoietic stem cell transplantation, (ASCT) were included. Their median age...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404833

    authors: Ringdén O,Uzunel M,Sundberg B,Lönnies L,Nava S,Gustafsson J,Henningsohn L,Le Blanc K

    更新日期:2007-11-01 00:00:00

  • Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes.

    abstract::Specific myeloid-related and inositide-specific gene mutations can be linked to myelodysplastic syndromes (MDS) pathogenesis and therapy. Here, 44 higher-risk MDS patients were treated with azacitidine and lenalidomide and mutations analyses were performed at baseline and during the therapy. Results were then correlat...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-019-0416-x

    authors: Follo MY,Pellagatti A,Armstrong RN,Ratti S,Mongiorgi S,De Fanti S,Bochicchio MT,Russo D,Gobbi M,Miglino M,Parisi S,Martinelli G,Cavo M,Luiselli D,McCubrey JA,Suh PG,Manzoli L,Boultwood J,Finelli C,Cocco L

    更新日期:2019-09-01 00:00:00

  • Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy.

    abstract::This study investigated the relationships between HDL-C and major types of blood cancers. Competing risks regression was used to examine the hazard ratios of hematologic malignancies in 9,596,145 individuals (≥20 years) using data from the Korean National Health Insurance Service (2009-2017). The incidence of the foll...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/s41375-020-01081-5

    authors: Jeong SM,Choi T,Kim D,Han K,Kim SJ,Rhee SY,Giovannucci EL,Shin DW

    更新日期:2020-12-02 00:00:00

  • Insulin is a potent myeloma cell growth factor through insulin/IGF-1 hybrid receptor activation.

    abstract::Insulin and insulin growth factor type 1 (IGF-1) and their receptors are closely related molecules, but both factors bind to the receptor of the other one with a weak affinity. No study has presently documented a role of insulin as a myeloma growth factor (MGF) for human multiple myeloma cells (MMCs), whereas many stu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2010.192

    authors: Sprynski AC,Hose D,Kassambara A,Vincent L,Jourdan M,Rossi JF,Goldschmidt H,Klein B

    更新日期:2010-11-01 00:00:00

  • DNA profiling analysis of 100 consecutive de novo acute myeloid leukemia cases reveals patterns of genomic instability that affect all cytogenetic risk groups.

    abstract::We have carried out a high-resolution whole genome DNA profiling analysis on 100 bone marrow samples from a consecutive series of de novo acute myeloid leukemia (AML) cases. After discarding copy number changes that are known to be genetic polymorphisms, we found that genomic aberrations (GA) in the form of gains or l...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404653

    authors: Suela J,Alvarez S,Cifuentes F,Largo C,Ferreira BI,Blesa D,Ardanaz M,García R,Marquez JA,Odero MD,Calasanz MJ,Cigudosa JC

    更新日期:2007-06-01 00:00:00

  • Detection of minimal residual disease in patients with AML1/ETO-associated acute myeloid leukemia using a novel quantitative reverse transcription polymerase chain reaction assay.

    abstract::The AML1/ETO fusion transcript can be detected by reverse transcription polymerase chain reaction (RT-PCR) in patients with t(8;21)-associated acute myeloid leukemia (AML) in long-term complete remission (CR). Quantitation of the amount of the fusion transcript during CR may therefore be more predictive of cure or rel...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401128

    authors: Marcucci G,Livak KJ,Bi W,Strout MP,Bloomfield CD,Caligiuri MA

    更新日期:1998-09-01 00:00:00

  • AKT collaborates with ERG and Gata1s to dysregulate megakaryopoiesis and promote AMKL.

    abstract::The requirement that leukemic Gata1 mutations be present in cells harboring trisomy 21 led to the discovery that overexpression of ERG drives aberrant megakaryopoiesis. Given that constitutive PI3K/AKT signaling is a frequent component of hematologic malignancies and the relationship between AKT and Notch in this line...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.33

    authors: Stankiewicz MJ,Crispino JD

    更新日期:2013-06-01 00:00:00

  • Validity of the in vitro system as a correlate of the in vivo model of RadLV lymphomagnesis.

    abstract::Adult BL/6 mice are highly sensitive to lymphomagnesis by the radiation leukemia virus variant A-RadLV (80-100% T-cell lymphoma incidence after a latency of 70-110 days). This study shows that the in vivo elimination of T-cell subsets (including suppressor and cytotoxic T-cells) achieved by the repeated administration...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Haran-Ghera N,Peled A

    更新日期:1991-06-01 00:00:00

  • Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured?

    abstract::The concept of applying all active therapeutic agents in Total Therapy (TT) clinical trials for newly diagnosed multiple myeloma was pursued with the intent of developing curative treatment. The results of TT1 (n=231), TT2 (n=668) without or with thalidomide and TT3 with added bortezomib (n=303) have been reported. An...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.160

    authors: Usmani SZ,Crowley J,Hoering A,Mitchell A,Waheed S,Nair B,AlSayed Y,Vanrhee F,Barlogie B

    更新日期:2013-01-01 00:00:00

  • Establishment of the B cell precursor acute lymphoblastic leukemia cell line MUTZ-5 carrying a (12:13) translocation.

    abstract::Continuous leukemia-lymphoma cell lines are important research tools, in particular as starting material for the cloning of recurrent translocations. In 1998, we established the continuous leukemia cell line MUTZ-5 and its two simultaneous sister cell lines MUTZ-6 and MUTZ-7. The primary specimen was obtained from the...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402212

    authors: Meyer C,MacLeod RA,Quentmeier H,Janssen JW,Coignet LJ,Dyer MJ,Drexler HG

    更新日期:2001-09-01 00:00:00

  • Somatic mitochondrial DNA mutations in adult-onset leukaemia.

    abstract::Mitochondrial genome instability has recently been demonstrated in a wide variety of human tumours and is implicated in the development of the myelodysplastic syndromes, a heterogeneous group of haematological disorders with an increased risk of malignant transformation. We therefore investigated the incidence of soma...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403146

    authors: He L,Luo L,Proctor SJ,Middleton PG,Blakely EL,Taylor RW,Turnbull DM

    更新日期:2003-12-01 00:00:00

  • High activity of sorafenib in FLT3-ITD-positive acute myeloid leukemia synergizes with allo-immune effects to induce sustained responses.

    abstract::Preliminary evidence suggests that the multikinase inhibitor sorafenib has clinical activity in FLT3-ITD-positive (FLT3-ITD) acute myeloid leukemia (AML). However, the quality and sustainability of achievable remissions and clinical variables that influence the outcome of sorafenib monotherapy are largely undefined. T...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.105

    authors: Metzelder SK,Schroeder T,Finck A,Scholl S,Fey M,Götze K,Linn YC,Kröger M,Reiter A,Salih HR,Heinicke T,Stuhlmann R,Müller L,Giagounidis A,Meyer RG,Brugger W,Vöhringer M,Dreger P,Mori M,Basara N,Schäfer-Eckart K,S

    更新日期:2012-11-01 00:00:00

  • HTLV-1 uveitis (HU).

    abstract::We reported HTLV-1 uveitis (HU) as the third distinct clinical entity associated with HTLV-1 infection. Uveitis has advantages for studying the pathogenetic mechanisms of inflammatory diseases caused by HTLV-1, since observation of the disease process is relatively easy and clinical samples from the lesion can be obta...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Watanabe T,Mochizuki M,Yamaguchi K

    更新日期:1997-04-01 00:00:00

  • Ectopic retroviral expression of LMO2, but not IL2Rgamma, blocks human T-cell development from CD34+ cells: implications for leukemogenesis in gene therapy.

    abstract::The occurrence of leukemia in a gene therapy trial for SCID-X1 has highlighted insertional mutagenesis as an adverse effect. Although retroviral integration near the T-cell acute lymphoblastic leukemia (T-ALL) oncogene LIM-only protein 2 (LMO2) appears to be a common event, it is unclear why LMO2 was preferentially ta...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404563

    authors: Pike-Overzet K,de Ridder D,Weerkamp F,Baert MR,Verstegen MM,Brugman MH,Howe SJ,Reinders MJ,Thrasher AJ,Wagemaker G,van Dongen JJ,Staal FJ

    更新日期:2007-04-01 00:00:00

  • Expression of tie receptor tyrosine kinase in leukemia cell lines.

    abstract::The tie receptor tyrosine kinase mRNA was originally identified as an amplified product in reverse transcription-polymerase chain reaction analysis of human K562 leukemia cell RNA. In situ hybridization analysis revealed that the corresponding mouse gene is expressed predominantly in endothelial cells. We have explore...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Armstrong E,Korhonen J,Silvennoinen O,Cleveland JL,Lieberman MA,Alitalo R

    更新日期:1993-10-01 00:00:00

  • Role of cytokines in the treatment of acute leukemias: a review.

    abstract::Myeloid growth factors, such as granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor, have been used to decrease the duration of chemotherapy-induced neutropenia and thereby reduce the incidence and severity of infections in various regimens used to treat acute myeloid leukemia an...

    journal_title:Leukemia

    pub_type: 杂志文章,评审

    doi:10.1038/sj.leu.2404152

    authors: Ravandi F

    更新日期:2006-04-01 00:00:00

  • Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002.

    abstract::Novel approaches have been designed to treat leukemia based on our understanding of the genetic and biochemical lesions present in different malignancies. This meeting report summarizes some of the recent advances in leukemia treatment. Based on the discoveries of cellular oncogenes, chromosomal translocations, monocl...

    journal_title:Leukemia

    pub_type:

    doi:10.1038/sj.leu.2403156

    authors: Larson RA,Daley GQ,Schiffer CA,Porcu P,Pui CH,Marie JP,Steelman LS,Bertrand FE,McCubrey JA

    更新日期:2003-12-01 00:00:00

  • The product of the proto-oncogene c-kit (P145c-kit) is a human bone marrow surface antigen of hemopoietic precursor cells which is expressed on a subset of acute non-lymphoblastic leukemic cells.

    abstract::A monoclonal antibody (17F11) was raised by immunization of a Balb/c mouse with leukemic blasts from a patient with acute non-lymphocytic leukemia (ANLL). This antibody recognizes most leukemic blasts of myeloid but not of lymphoid lineage and no peripheral blood cells. By screening NIH-3T3 fibroblasts transfected wit...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bühring HJ,Ullrich A,Schaudt K,Müller CA,Busch FW

    更新日期:1991-10-01 00:00:00

  • Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis.

    abstract::Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional symptoms. Pomalidomide, an immune-modifying drug, is reported to improve anaemia and thrombocytopenia in some patients with MPN-associated myelofibrosis. We designed a ...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/leu.2016.299

    authors: Schlenk RF,Stegelmann F,Reiter A,Jost E,Gattermann N,Hebart H,Waller C,Hochhaus A,Platzbecker U,Schafhausen P,Blau IW,Verbeek W,Heidel FH,Werner M,Kreipe H,Teleanu V,Benner A,Döhner H,Grießhammer M,Döhner K

    更新日期:2017-04-01 00:00:00

  • Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib.

    abstract::Drug resistance is a growing area of concern. It has been shown that a small, residual pool of leukemic CD34+ progenitor cells can survive in the marrow microenvironment of chronic myeloid leukemia (CML) patients after years of kinase inhibitor treatment. Bone marrow (BM) stroma has been implicated in the long-term su...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.360

    authors: Weisberg E,Azab AK,Manley PW,Kung AL,Christie AL,Bronson R,Ghobrial IM,Griffin JD

    更新日期:2012-05-01 00:00:00